GermanyGermany

German and Swedish Cancer Researchers Join Forces

23.11.2003

Erlangen/Stockholm - The German biotech company responsif GmbH and scientists from the prestigious Karolinska Institute in Stockholm, Sweden, have recently signed a cooperation agreement, which will bring a promising new treatment for cancer one step closer to clinical trials. The Swedish cancer researchers working in the Department of Oncology & Pathology in the Section for Experimental Oncology are now using an “anchoring” technique developed by responsif to pack tumour antigens into virus capsoids. The aim is to create an anti-tumour vaccine, which will mobilise the body's own immune defences against cancer cells.
As part of the cooperation agreement, the Swedish scientists have obtained a license option for the specific use of the anchor technology. The agreement also gives them the option of acquiring industrial partners within the next two years to assist them in developing this technology up to market maturity.
“Our consistent patent strategy has proved to be the right one”, commented Dr. Christian Reiser, Managing Director of responsif, recently at the BioTechnica in Hannover, Germany. “We are very pleased that these clinicians plan to deploy the anchor technology developed by responsif in the battle against cancer.”
With the licensing agreement, the two partners have also entered into a scientific collaboration aimed at advancing the preclinical investigation of an anti-tumour vaccine based on the viral capsoid technology developed by the biotechnologists in Erlangen. The capsoid technology evolved from the idea of using Polyoma virus-like particles (VLPs) as delivery systems for tumour antigens. Since these particles do not contain any viral genetic information, moreover, they are not infectious.
In addition to the anchor technology, responsif GmbH is working on another immunotherapeutic approach using autologous cancer cells from patients with advanced stage cancer. The company is a spin-off of the former Division of Molecular Therapy at november AG, a biotech company traded in the Prime Standard segment of the German Stock Exchange.

GermanyGermany

16.03.2007

Jena – Almost 200 former Eastern German athletes who suffered devastating side effects after being given steroids as part of their training regime before 1989, have each received a9.250 in compensation from the German...

GermanyGermany

16.03.2007

Berlin – After years of negotiations, the German governing coalition has agreed on principles for a new law on genetic engineering. Agriculture minister Horst Seehofer has evidently succeeded in resolving most of the key...

Austria, GermanyGermany

16.03.2007

Vienna/Berlin – Biotech and pharma organizations have criticized the new second-opinion system which the German government installed in the reform of the country’s healthcare system. With these measures, the government hopes to...

GermanyGermany

16.03.2007

Heidelberg – Scientists at Heidelberg University have successfully completed Germany’s first HIV experiments on rats implanted with human genes. The tests may provide a viable animal model for antiretroviral drugs testing that...

GermanyGermany

25.01.2007

Heidelberg – Ten young researchers have received an annual Euro 50,000 fund by European Molecular Biology Organization (EMBO) to relocate to European Union labs.

Germany, Tech ReviewGermany

12.01.2007

The almost complete sequencing of the genomes from numerous organisms paved the way for the development and application of new experimental and instrumental techniques which contribute to the understanding of complex biological...

BioFunding, Germany, SwitzerlandGermany

21.11.2006

The Austrian vaccines developer Intercell AG has won this year’s European BioTechnica Award and will certainly be pleased to receive a cheque for the sum of a20.000. Europe’s most prestigious prize for a young biotechnology...

Politics / Law, Germany, SwitzerlandGermany

21.11.2006

Following the European Commission’s green light for the merger of the two US lab suppliers Thermo Electron and Fisher Scientific, the market is expected to see a further consolidation. Industry analysts have commented that the...

Germany, SwitzerlandGermany

21.11.2006

Geneva – In a surprising move, Serono’s majority owner and CEO Ernesto Bertarelli has found a buyer for his company Serono. German drug maker Merck KGaA is to buy the 64.5% stake owned by the Swiss Bertarelli family. The bid of...

Germany, Tech ReviewGermany

21.11.2006

A newly identified receptor protein for the soluble vascular endothelial growth factor (VEGF) inhibits angiogenesis in the retina of patients with the aggressive wet form of age-related macula degeneration (AMD). With the help of...

Displaying results 271 to 280 out of 454

< Previous 271-280 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/27/article/german-and-swedish-cancer-researchers-join-forces.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014


Current issue

All issues

Product of the week

Products